Steffen K M, Cooper M E, Shi M, Caprau D, Simhan H N, Dagle J M, Marazita M L, Murray J C
University of Iowa College of Medicine, Iowa City, IA 52242, USA.
J Perinatol. 2007 Nov;27(11):672-80. doi: 10.1038/sj.jp.7211806. Epub 2007 Sep 13.
To examine the contribution of variants in fetal and maternal cholesterol metabolism genes in preterm delivery (PTD).
A total of 40 single-nucleotide polymorphisms (SNPs) in 16 genes related to cholesterol metabolism were examined for 414 preterm infants (gestational ages 22 to 36 weeks; comprising 305 singletons and 109 twins) and at least 1 parent. Fetal effects were assessed using the transmission disequilibrium test (TDT) for each SNP, followed by a log linear model-based approach to utilize families with missing parental genotypes for those SNPs showing significance under TDT. Genetic variant effects were examined for a role in PTD, gestational age and birth weight. Maternal effects were estimated using a log linear model-based approach.
Among singleton gestations, suggestive association (P<0.01 without adjusting for multiple comparisons) was found between birth weight and fetal DHCR7 gene/SNP combinations (rs1630498, P=0.002 and rs2002064, P=0.003). Among all gestations, suggestive associations were found between PTD and fetal HMGCR (rs2303152, P=0.002) and APOA1 (rs 5070, P=0.004). The result for HMGCR was further supported by the log linear model-based test in the single births (P=0.007) and in all births (P=0.006). New associations (APOE and ABCA1) were observed when birth weight was normalized for gestational age suggesting independent effects of variants on birth weight separate from effects on PTD. Testing for maternally mediated genetic effects has identified suggestive association between ABCA1 (rs4149313, P=0.004) and decreased gestational age.
Variants in maternal and fetal genes for cholesterol metabolism were associated with PTD and decreased birth weight or gestational age in this study. Genetic markers may serve as one mechanism to identify high-risk mothers and fetuses for targeted nutritional treatment and/or prevention of low birth weight or PTD.
研究胎儿和母体胆固醇代谢基因变异在早产(PTD)中的作用。
对414例早产儿(胎龄22至36周;包括305例单胎和109例双胎)及其至少1名父母,检测了16个与胆固醇代谢相关基因中的40个单核苷酸多态性(SNP)。使用传递不平衡检验(TDT)评估每个SNP的胎儿效应,随后采用基于对数线性模型的方法,对在TDT下显示出显著性的SNP,利用缺失父母基因型的家庭进行分析。研究基因变异在早产、胎龄和出生体重中的作用。使用基于对数线性模型的方法估计母体效应。
在单胎妊娠中,出生体重与胎儿DHCR7基因/SNP组合(rs1630498,P = 0.002;rs2002064,P = 0.003)之间存在提示性关联(未校正多重比较时P<0.01)。在所有妊娠中,早产与胎儿HMGCR(rs2303152,P = 0.002)和APOA1(rs5070,P = 0.004)之间存在提示性关联。单胎出生(P = 0.007)和所有出生(P = 0.006)的对数线性模型检验进一步支持了HMGCR的结果。当根据胎龄对出生体重进行标准化时,观察到新的关联(APOE和ABCA1),表明变异对出生体重的独立影响与对早产的影响不同。对母体介导的遗传效应进行检测,发现ABCA1(rs4149313,P = 0.004)与胎龄降低之间存在提示性关联。
本研究中,母体和胎儿胆固醇代谢基因的变异与早产以及出生体重或胎龄降低有关。遗传标记可作为一种机制,用于识别高危母亲和胎儿,以便进行针对性的营养治疗和/或预防低出生体重或早产。